帕金森病聚焦超声单侧丘脑底核毁损术的前瞻性长期随访
这项前瞻性开放标签研究纳入32例不对称帕金森病患者,接受单侧磁共振引导聚焦超声丘脑底核毁损术(FUS-STN),随访至36个月。结果显示治疗侧半身关药状态下MDS-UPDRS III评分从基线19.0±3.2降至8.9±3.3,改善52.3%(95% CI 8.7至11.6,p<0.001),且未报告致残性或迟发性不良事件。
要点
- 单侧FUS-STN治疗侧半身关药MDS-UPDRS III评分3年改善52.3%。
- 关药总MDS-UPDRS III评分3年较基线降低22.9%(95% CI 6.0至11.5,p<0.001)。
- 未报告致残性或迟发性不良事件,MDS-UPDRS II、IV、PDQ39及左旋多巴剂量与基线相当。
核心结论
- 单侧FUS-STN对帕金森病运动特征的获益在长期随访中持续存在。
- FUS-STN有助于在数年病程演变中实现更好的临床控制。
- 本研究提供IV级证据支持聚焦超声单侧丘脑底核毁损术用于帕金森病患者的治疗。
研究设计与样本
- 前瞻性开放标签研究,纳入不对称帕金森病患者,接受单侧FUS-STN治疗。
- 所有患者随访至治疗后36个月,共32例患者在治疗36个月后完成评估。
- 基线平均年龄56.0±10.1岁,平均病程6.8±2.8年。
主要发现
- 治疗侧半身关药MDS-UPDRS III评分从基线19.0±3.2降至3年8.9±3.3,改善52.3%(95% CI 8.7至11.6,p<0.001)。
- 关药总MDS-UPDRS III评分3年较治疗前降低22.9%(36.8±7.4 vs 27.4±6.2,95% CI 6.0至11.5,p<0.001)。
- 所有具体运动特征(强直、运动迟缓、震颤、轴向特征)均较基线改善。
- 未报告致残性或迟发性不良事件。
- MDS-UPDRS II、IV、PDQ39评分及左旋多巴剂量与基线相当。
关键数值与推荐
- 主要结局为治疗侧半身关药MDS-UPDRS III评分从基线至36个月的变化。
- 安全性结局包括随访期间发生的所有不良事件。
- 次要结局包括开药MDS-UPDRS III评分、强直/运动迟缓/震颤/轴向特征亚评分、总MDS-UPDRS III及MDS-UPDRS IV评分。
- 功能残疾和生活质量分别用MDS-UPDRS II和PDQ39评估。
- 数据分析采用Wilcoxon符号秩检验并随后进行Bonferroni校正。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Unilateral magnetic resonance-guided focused ultrasound subthalamotomy (FUS-STN) has been shown to improve the cardinal motor features of Parkinson disease (PD). Whether this effect is sustained is not known. This study aims to report the long-term outcome of patients with PD treated with unilateral FUS-STN. METHODS: We conducted a prospective open-label study of patients with asymmetrical PD who underwent unilateral FUS-STN. All patients were evaluated up to 36 months after treatment. The primary outcome was the difference from baseline to 36 months after FUS-STN in the score of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor part (III) for the treated hemibody in the off-medication state. The safety outcome included all adverse events occurring during follow-up. Secondary outcomes were the change in the MDS-UPDRS III score on-medication; subscores of rigidity, bradykinesia, tremor, and axial features; total MDS-UPDRS III; and the MDS-UPDRS part IV. Functional disability and quality of life were assessed using the MDS-UPDRS II and the PDQ39, respectively. Patient impression of change and satisfaction with the treatment were self-assessed. The Wilcoxon signed-rank test with subsequent Bonferroni's correction was used for data analysis. RESULTS: Thirty-two patients with PD were evaluated at 36 months after treatment. The mean (±SD) age at baseline was 56.0 ± 10.1 years, with a mean disease duration of 6.8 ± 2.8 years. The MDS-UPDRS III score for the treated hemibody off-medication was improved by 52.3% from baseline to 3 years (score reduction from 19.0 ± 3.2 to 8.9 ± 3.3, 95% CI 8.7 to 11.6, p < 0.001), and all specific motor features were improved from baseline. No disabling or delayed adverse events were reported. The total MDS-UPDRS III off-medication score was 22.9% lower at 3 years than before treatment (36.8 ± 7.4 vs 27.4 ± 6.2, 95% CI 6.0 to 11.5, p < 0.001). The MDS-UPDRS II, IV, and PDQ39 scores and levodopa dose were equivalent to those at baseline. DISCUSSION: The benefit of unilateral FUS-STN on PD motor features is sustained in the long term. FUS-STN contributes to better clinical control over several years of evolution. NCT02912871/03454425. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence on the utility of focused ultrasound unilateral subthalamotomy in the treatment of people with Parkinson disease.
引用
- Martínez-Fernández R, Natera-Villalba E, Máñez Miró JU, et al. Prospective Long-term Follow-up of Focused Ultrasound Unilateral Subthalamotomy for Parkinson Disease. Neurology. 2023. PMID: 36631272. doi:10.1212/WNL.0000000000206771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。